Cas 943609-66-3 Vedolizumab Monoclonal Antibodies For Cancer Treatment
Cas 943609-66-3 Vedolizumab Monoclonal Antibodies For Cancer Treatment
| Product name:Vedolizumab | Purity:99% min |
| CAS NO:943609-66-3 | Solubility: |
| Molecular Formula:C6528H10072N1732O2042S42 | Package:Package according to customer requirements |
| Molecular Weight:146.8 kg/mol | Storage:Store at -20℃ |
Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc (a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn's disease.It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1).Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.It is marketed under the trade name Entyvio.
Related Products:
Alirocumab; Denosumab; Eculizumab; Evolocumab; Omalizumab; Ustekinumab; Trastuzumab; Omalizumab; Nivolumab; Denosumab; Cetuximab; Bevacizumab; Aflibercept
[1]. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75.
[2]. Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):4-9.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.